Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...